ArticleCancer management and research2019
Prognostic analysis of patients with mutant and wild-type
Article in Cancer management and research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Development and Validation of a Prognostic Nomogram for Lung Adenocarcinoma: A Population-Based Study.Journal of healthcare engineering · 2022Trial
- Brain metastasis magnetic resonance imaging-based deep learning for predicting epidermal growth factor receptor (Quantitative imaging in medicine and surgery · 2024Article
- Article
- Biological evaluation, docking studies, andJournal of enzyme inhibition and medicinal chemistry · 2023Article
- Article
- Aberrant Expression of β-Catenin Correlates with Infiltrating Immune Cells and Prognosis in NSCLC.Pathology oncology research : POR · 2021Article
- 3D radiomics predicts EGFR mutation, exon-19 deletion and exon-21 L858R mutation in lung adenocarcinoma.Translational lung cancer research · 2020Article
- Upregulated expression of pyruvate kinase M2 mRNA predicts poor prognosis in lung adenocarcinoma.PeerJ · 2020Article
- Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study.Cancer management and research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study was to investigate the relationship between epidermal growth factor receptor (
methods
resultsThe total
conclusionThe OS time of patients with mutation of exon 18 was lower than those of exon 19 and exon 21. EGFR-TKI treatment was an independent positive predictor in patients with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.